Earnings call· Jun 2026(Q2 FY26)

NexPoint Real Estate Finance Q2 FY26 earnings call NREF

Aug 6, 2026 Source

Executive summary

NexPoint Real Estate Finance Q2 FY26 — Strong Execution and Capital Structure Optimization

NexPoint Real Estate Finance delivered solid Q2 FY26 results, marked by strong execution in capital structure optimization and accretive new investments. The company observed positive inflection points in residential lease trade-outs and significant de-risking in its life science portfolio, positioning it well for future growth amidst a favorable supply-demand outlook.

Highlights

5

Cash available for distribution (CAD) increased to $0.58 per diluted share in Q2 FY26, up from $0.46 in Q2 FY25.
Q2 FY26 dividend of $0.50 per share was 1.16x covered by CAD.
Successfully refinanced $180 million senior unsecured notes with a new $375 million drawable term loan facility, enhancing balance sheet flexibility.
Residential blended lease trade-outs turned positive at +30 basis points in July, indicating improving fundamentals.
Alewife life science property reached 85% leased, up from 71%, anchored by a 245,000 sq ft long-term lease.

Concerns

3

Book value per diluted share decreased by 1.9% to $18.60, primarily due to an unrealized loss on the stock warrant portfolio.
Earnings available for distribution (EAD) has been below the dividend for several quarters, despite CAD coverage.
New lease trade-outs in the residential portfolio continue to be a drag on overall performance.

Guidance & targets

6

Category	Target	Timeline	Confidence
Earnings available for distribution (EAD) per diluted share	$0.43 high materiality	Q3 · FY26	High
Earnings available for distribution (EAD) per diluted share range (low end)	$0.38 medium materiality	Q3 · FY26	High
Earnings available for distribution (EAD) per diluted share range (high end)	$0.48 medium materiality	Q3 · FY26	High
Cash available for distribution (CAD) per diluted share	$0.55 high materiality	Q3 · FY26	High
Cash available for distribution (CAD) per diluted share range (low end)	$0.50 medium materiality	Q3 · FY26	High
Cash available for distribution (CAD) per diluted share range (high end)	$0.60 medium materiality	Q3 · FY26	High

Operational metrics

44

Earnings available for distribution (EAD) per diluted share

$0.46up from $0.43 in Q2 FY25

Q2 FY26

Reported for the quarter.

Cash available for distribution (CAD) per diluted share

$0.58up from $0.46 in Q2 FY25

Q2 FY26

Reported for the quarter.

Dividend per share

$0.50

Q2 FY26

Regular dividend paid in Q2 FY26. Also declared for Q3 FY26.

Dividend coverage by CAD

1.16x

Q2 FY26

Dividend covered by cash available for distribution.

Book value per diluted share

$18.60decreased 1.9% from Q1 FY26

Q2 FY26

Primarily driven by unrealized loss on stock warrant portfolio.

Preferred equity investment

$20.2M

Q2 FY26

New investment funded during the quarter.

Mezzanine loan

$42.6M

Q2 FY26

New investment funded during the quarter.

Additional funding on existing commitments

$31.9M

Q2 FY26

Funded during the quarter.

Outstanding balance on drawable term loan facility

$362.2M

as of 2026-08-06

Facility closed to repay senior unsecured notes.

TRS net interest cost

SOFR + 2.45%

ongoing

Total Return Swap with Mizuho reduces net interest costs.

Series C preferred offering proceeds

$22.6M

Q2 FY26

Capital raised during the quarter.

Total portfolio outstanding balance

$1.1B

Q2 FY26

Comprised of 85 investments.

Portfolio allocation by sector

39.4%

Q2 FY26

Allocation of total portfolio investments.

Portfolio allocation by sector

37.6%

Q2 FY26

Allocation of total portfolio investments.

Portfolio allocation by sector

15.1%

Q2 FY26

Allocation of total portfolio investments.

Portfolio allocation by sector

4.2%

Q2 FY26

Allocation of total portfolio investments.

Portfolio allocation by sector

2.1%

Q2 FY26

Allocation of total portfolio investments.

Portfolio allocation by sector

1.6%

Q2 FY26

Allocation of total portfolio investments.

Fixed income portfolio allocation

27.8%

Q2 FY26

Allocation of fixed income portfolio.

Fixed income portfolio allocation

24.9%

Q2 FY26

Allocation of fixed income portfolio.

Fixed income portfolio allocation

17.5%

Q2 FY26

Allocation of fixed income portfolio.

Fixed income portfolio allocation

17.3%

Q2 FY26

Allocation of fixed income portfolio.

Fixed income portfolio allocation

6.2%

Q2 FY26

Allocation of fixed income portfolio.

Fixed income portfolio allocation

4%

Q2 FY26

Allocation of fixed income portfolio.

Fixed income portfolio allocation

2.2%

Q2 FY26

Allocation of fixed income portfolio.

Geographic allocation

31.2%

Q2 FY26

Geographic allocation of collateral, heavily weighted towards life science.

Geographic allocation

16%

Q2 FY26

Geographic allocation of collateral.

Geographic allocation

6%

Q2 FY26

Geographic allocation of collateral.

Geographic allocation

4.6%

Q2 FY26

Geographic allocation of collateral.

Geographic allocation

5.2%

Q2 FY26

Geographic allocation of collateral, heavily weighted towards life science.

Geographic allocation

4.7%

Q2 FY26

Geographic allocation of collateral.

Portfolio collateral stabilized

80.3%

Q2 FY26

Percentage of collateral that is stabilized.

Portfolio loan-to-value (LTV)

63.4%

Q2 FY26

Weighted average loan-to-value for the portfolio.

Portfolio weighted average DSCR

1.39x

Q2 FY26

Weighted average Debt Service Coverage Ratio for the portfolio.

Weighted average cost of debt

6.3%

Q2 FY26

Weighted average cost of $836.6 million of debt outstanding.

Weighted average maturity of debt

2.6 years

Q2 FY26

Weighted average maturity of debt outstanding.

Secured debt collateral value

$1.4B

Q2 FY26

Collateralizing secured debt.

Weighted average maturity of collateral

2.7 years

Q2 FY26

Weighted average maturity of collateral for secured debt.

Debt-to-equity ratio

0.88x

Q2 FY26

Reported debt-to-equity ratio.

Residential blended lease trade-outs

+30 bpsfrom -50 bps in June

July

First positive blended print since early 2025.

Multifamily net deliveries

695,000 unitsvs 282,000 units average annual since 2001

TTM Q4 2024

Peak deliveries, according to CoStar.

Multifamily starts

70% below2022 peak

current

Indicative of declining future supply.

Cost to own vs. cost to rent ratio

3x

current

Structural backdrop supporting residential demand.

Life science tours and TIMs (Tenants in Market)

up 30%sequentially over Q1 FY26

Q2 FY26

Indicating improving demand funnel.

Industry KPIs

5

Metric	Value	Period	Details
Occupancy rate	85%%	Q2 FY26
Investment volume closed	$94.7MUSD	Q2 FY26
Leasing bookings volume signed	245,000 square feetsq ft	Q2 FY26
Ffo core ffo normalized ffo per share	$0.58USD	Q2 FY26
Lease renewal spread re leasing recapture	+30 bpsbps	July

Orderbook & backlog

1

NREF investment across active deals$190 million-plusApril 2026

Represents 11 active deals in the pipeline, with over $70 million closed in Q2 FY26.

Deals & partnerships

3

Mizuho Capital MarketsDrawable term loan facility$375 million

Closed a $375 million drawable term loan facility with Mizuho Capital Markets, used to repay $180 million, 5.75% senior unsecured notes at their May 1 maturity. $362.2 million outstanding as of call date.

MizuhoTotal Return Swap (TRS)

Concurrently entered into a TRS with Mizuho to reduce net interest costs.

Lila SciencesLong-term lease for life science propertylong-term

Lila Sciences signed a long-term lease for 245,000 square feet with expansion options at the Alewife property.

Risks & headwinds

3

Book value decline due to unrealized lossesQ2 FY26

Book value per diluted share decreased by 1.9% from Q1 2026 to $18.60.

Mitigation: Primarily driven by a small unrealized loss on the stock warrant portfolio, implying it's not operational.

New lease trade-outs remain a dragQ2 FY26

New lease trade-outs remain the drag on residential performance.

Mitigation: Renewals have been holding up well, and blended lease trade-outs turned positive in July.

EAD below dividendmultiple quarters

Earnings available for distribution has been below the dividend for several quarters.

Mitigation: Dividend is 1.16x covered by Cash available for distribution (CAD), which is the gold standard for distributions. EAD and CAD are expected to converge over time.

What to watch in Q3 FY26

5

Alewife refi completion and capital redeployment

Q4 FY26

CurrentSponsor running refi process; capital expected back.

TargetRefi completed, substantial capital returned, and redeployed into residential assets.

Why it matters

This will free up significant capital for new investments, primarily in residential, impacting future portfolio composition and returns.

The sponsor on Alewife is out running a refi process to recap the Alewife whole campus, and we would get a substantial amount of capital back to then go redeploy. And our goal would be to probably redeploy most of those proceeds into residential assets.

Q&A highlights

4

How does management view the long-term portfolio allocation between life sciences and multifamily, especially given the recent increase in life science exposure and the AI theme?

Management aims for life science/advanced manufacturing to be about one-third of the portfolio and residential around 50% in a normalized environment. The Alewife life science asset was a unique opportunity, and capital returned from its expected Q4 refinancing will likely be redeployed into residential assets.

“I think in a normalized environment, we'd probably like to keep life sciences to be about a 1/3 -- or I'd say life science and advanced manufacturing, kind of biomanufacturing, those type of assets in around 1/3 of the pie chart. Obviously, in the recent kind of 12 to 18 months, Alewife is a one-off, pretty special opportunity that we were able to take advantage of.”

asked by Crispin Love · answered by Matthew McGraner

2 min read5 chapters

Detailed Narrative

01

Capital Structure & Liquidity

The company significantly enhanced its capital structure by closing a $375 million drawable term loan facility with Mizuho Capital Markets, which was used to repay $180 million of 5.75% senior unsecured notes. Concurrently, a Total Return Swap (TRS) was entered into with Mizuho, reducing net interest costs to SOFR plus 2.45%. This transaction removed a major near-term liability and provides a flexible, asset-based financing structure, positioning the company with one of the cleanest capital structures in the commercial mortgage REIT sector.

02

Residential Market Fundamentals

Residential fundamentals are showing signs of turning, with blended lease trade-outs improving from -1.7% in April to +30 basis points in July, marking the first positive print since early 2025. While new lease trade-outs remain a drag, renewals are holding up well. CoStar forecasts a 49% decline in 2026 multifamily deliveries from 2025, with another 20% decline in 2027, suggesting a return of pricing power as supply troughs. The structural backdrop remains favorable, with the cost to own in their markets roughly 3x the cost to rent.

03

Life Science Portfolio Performance

The Alewife life science property is now 85% leased, a significant increase from 71%, anchored by Lila Sciences with a long-term lease for 245,000 square feet. The demand funnel for life science collateral has widened materially due to AI companies requiring purpose-built infrastructure with specific power density, cooling capacity, and structural loads. Management anticipates a capital return from the Alewife refi process in Q4, with proceeds intended for redeployment into residential assets.

04

Investment Activity & Pipeline

NREF funded $20.2 million in a preferred equity investment (14% coupon) and a $42.6 million mezzanine loan (14% coupon) in Q2, alongside $31.9 million in additional funding on existing commitments. The company successfully closed over $70 million from its pipeline of active deals, which had been previously outlined at over $190 million across 11 deals, with blended returns exceeding the cost of capital on the TRS facility.

05

Credit Quality & Portfolio Composition

The portfolio, comprising 85 investments with a total outstanding balance of $1.1 billion, is 80.3% stabilized with a 63.4% loan-to-value and a weighted average DSCR of 1.39x. The company emphasizes its focus on agency-quality assets, largely avoiding the non-bank floating-rate bridge loans that have caused issues for some peers. Most of its preferred equity book collateral sits behind agency loans, contributing to strong credit performance across its multifamily and B-Piece exposures.

AI-generated summary of the company’s earnings call. Not investment advice.